Search clinical trials for: Keynote

Total 333 results

BioInvent International AB
Merck Sharp & Dohme LLC

Recruiting

BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

Hepatocellular Carcinoma | Non Small Cell Lung Cancer | Solid Tumors

Spain, Denmark, Poland, Sweden
University of Leipzig
University of Kiel; University of Cologne; University of Jena; Technical University... and other collaborators

Not yet recruiting

European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] (ELOS)

Laryngeal Cancer | Squamous Cell Carcinoma of Head and Neck | Laryngeal Neoplasms | Squamous Cell Carcinoma of the Larynx | Hypopharyngeal Squamous Cell Carcinoma | Laryngeal Squamous Cell Carcinoma | Laryngectomy; Status | Squamous Cell Carcinoma of Larynx | Squamous Cell Carcinoma of the Larynx Stage... and other conditions
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

Lung Cancer

United States
Servier Bio-Innovation LLC
Merck Sharp & Dohme LLC; Institut de Recherches Internationales Servier

Not yet recruiting

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

MSI-H/dMMR Gastroesophageal-junction Cancer | MSI-H/dMMR Gastric Cancer
Jazz Pharmaceuticals
Merck Sharp & Dohme LLC

Recruiting

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

Advanced Solid Tumor | Metastatic Solid Tumor

United States
Evopoint Biosciences Inc.
Merck Sharp & Dohme LLC

Recruiting

Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

Carcinoma | Cervical Cancer | Prostate Cancer | Squamous Cell Carcinoma of Head and Neck | Non-small Cell Lung Cancer | Small-cell Lung Cancer | Urothelial Carcinoma | Other Solid Tumors

China
Nykode Therapeutics ASA
Merck Sharp & Dohme LLC

Recruiting

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma

HNSCC | HPV-Related Squamous Cell Carcinoma

France, Norway, Spain, United Kingdom, Hungary, Poland, Czechia, Germany
Genome & Company
Merck Sharp & Dohme LLC

Recruiting

GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

Biliary Tract Cancer

Korea, Republic of
PharmAbcine
Merck Sharp & Dohme LLC; Novotech (Australia) Pty Limited

Not yet recruiting

Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 (MarkV-01)

Advanced or Metastatic Solid Tumors

Australia
Pfizer
Merck Sharpe & Dohme LLC

Recruiting

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma (PORTSIDE)

Melanoma

Italy, Spain, Czechia, Germany, Slovakia, Poland, United Kingdom
Seagen Inc.
Merck Sharp & Dohme LLC; RemeGen Co., Ltd.

Recruiting

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Urothelial Carcinoma

United States, Canada, Australia, Singapore
Wellmarker Bio
Merck Sharp & Dohme LLC

Recruiting

Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)

Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Advanced Solid Tumor | Metastatic Solid Tumor

Korea, Republic of
SignalChem Lifesciences Corporation
Merck Sharp & Dohme LLC

Recruiting

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

Lung Cancer Metastatic | Lung Cancer, Nonsmall Cell | Lung Cancer Stage IV

United States, Canada
Zai Lab (Hong Kong), Ltd.
Merck Sharp & Dohme LLC; Zai Biopharmaceutical (Shanghai) Co., Ltd.

Recruiting

A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors

Malignant Solid Tumor

United States, Spain, China
TiumBio Co., Ltd.
Merck Sharp & Dohme LLC

Recruiting

Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Solid Tumor

United States
ImmunOs Therapeutics AG
Merck Sharp & Dohme LLC

Recruiting

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

Solid Tumor, Adult

Australia
1ST Biotherapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

Advanced Solid Tumor

United States
Kineta Inc.
Merck Sharp & Dohme LLC

Recruiting

A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Melanoma | Sarcoma | Kidney Cancer | Carcinoma | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Solid Tumor | Prostate Cancer | Colo-rectal Cancer | Thyroid Cancer | Uterine Cancer

United States
Asher Biotherapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

Melanoma | Renal Cell Carcinoma | Solid Tumor | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck

United States
Eli Lilly and Company
Merck Sharp & Dohme LLC; Loxo Oncology, Inc.

Recruiting

A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3

Urinary Bladder Neoplasms | Neoplasm Metastasis | Ureteral Neoplasms

United States, Korea, Republic of, Spain, United Kingdom, Germany, Japan, France, China, Australia, Netherlands, Canada, Israel, Norway, Italy
Dragonfly Therapeutics
Merck Sharp & Dohme LLC

Recruiting

Study of DF9001 in Patients With Advanced Solid Tumors

Solid Tumor, Adult

United States
NextCure, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Endometrial Cancer | Colo-rectal Cancer | Advanced or Metastatic Solid Tumors | Microsatellite Instability Low | Microsatellite Instability High | Microsatellite Stable | Head Neck Cancer

United States
Tianjin Medical University Second Hospital

Recruiting

Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

China
Institut de Recherches Internationales Servier
Merck Sharp & Dohme LLC

Recruiting

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive Enhancing IDH-1 Mutant Glioma

Astrocytoma

United States
Phanes Therapeutics
Merck Sharp & Dohme LLC

Recruiting

PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study)

Pancreatic Ductal Adenocarcinoma | Gastric or Gastroesophageal Junction Adenocarcinoma

United States
Werewolf Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

Advanced Solid Tumor | Metastatic Solid Tumor

United States
AUM Biosciences Pte Ltd
Merck Sharp & Dohme LLC

Recruiting

MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Australia
Qurient Co., Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Cervical Cancer | Gastric Cancer | Esophageal Cancer | Hepatocellular Cancer

Korea, Republic of, United States
Adagene Inc
Merck Sharp & Dohme LLC

Recruiting

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors

Korea, Republic of, United States
Qurient Co., Ltd.
Merck Sharp & Dohme LLC

Recruiting

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Metastatic Cancer | Advanced Cancer

United States, Korea, Republic of
Gilead Sciences
Merck Sharp & Dohme LLC

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)

Triple Negative Breast Cancer | PD-L1 Positive

United States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
Nectin Therapeutics Ltd
Merck Sharp & Dohme LLC

Recruiting

A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

Cancer | Metastatic Cancer | Advanced Solid Tumor | Tumor, Solid | Locally Advanced Solid Tumor

United States, Israel
Lava Therapeutics
Merck Sharp & Dohme LLC

Recruiting

Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer

United States, Spain, Netherlands
Amunix, a Sanofi Company
Merck Sharp & Dohme LLC

Recruiting

To Access the Safety and Effects of Intravenous Administration of AMX-818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Locally Advanced or Metastatic HER2-Expressing Cancers

Australia, Spain, France, Portugal
Fujifilm Pharmaceuticals U.S.A., Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate Safety, Efficacy of FF-10832 in Combination With Pembrolizumab in Solid Tumors

Advanced Solid Tumor

United States
Evaxion Biotech A/S
Merck Sharp & Dohme LLC

Recruiting

A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

Melanoma Stage IV | Melanoma Stage III

Australia
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer. (PROTA)

Platinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Refractory Fallopian Tube Carcinoma | Platinum-Refractory Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma | Platinum-Sensitive Ovarian... and other conditions

United States, Finland
Pfizer
Eli Lilly and Company; Merck Sharp & Dohme LLC; Merck KGaA, Darmstadt, Germany

Recruiting

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (SEAMARK)

Metastatic Colorectal Cancer

United States, Denmark, Spain, Australia, France, Italy, Belgium, Slovakia, Canada, Czechia, Germany, Netherlands, Norway, Poland, Sweden, United Kingdom
NGM Biopharmaceuticals, Inc
Merck Sharp & Dohme LLC

Recruiting

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Non-small Cell Lung Cancer | Colorectal Carcinoma | Bladder Urothelial Cancer | Endocervical...

United States
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)

Metastatic Non Small Cell Lung Cancer

United States, China, Belgium, Portugal, Japan, Taiwan, France, United Kingdom, Spain, Hungary, Thailand, Germany, Italy, Switzerland, Hong Kong, Korea, Republic of, Australia, Mexico, Brazil, Netherlands, Romania, Argentina, Chile, G... and more
Antengene Therapeutics Limited
Merck Sharp & Dohme LLC

Recruiting

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors

Locally Advanced or Metastatic Solid Tumors

Australia, China
Jacobio Pharmaceuticals Co., Ltd.
Merck Sharp & Dohme LLC

Recruiting

JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Solid Tumor

China
Shionogi
Merck Sharp & Dohme LLC

Recruiting

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (aCCeleR8-001)

Solid Tumors

United States, Japan
Eisai Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

Melanoma | Carcinoma, Hepatocellular | Colorectal Neoplasms

Spain, United States, United Kingdom, Japan, France
Mural Oncology, Inc
Merck Sharp & Dohme LLC

Recruiting

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) (ARTISTRY-7)

Fallopian Tube Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Cancer

United States, Spain, Korea, Republic of, Taiwan, Canada, Israel, France, United Kingdom, Germany, Belgium, Czechia, Singapore, Australia, Austria, Italy
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions

United States, Australia, Korea, Republic of, Canada
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of ASP1570 Taken by Itself or With Pembrolizumab in Adults With Solid Tumors

Advanced Solid Tumors

United States, Japan
IO Biotech
Merck Sharp & Dohme LLC; Theradex; Almac; NeoGenomics

Recruiting

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma Bladder | Lung Cancer Non Small Cell

United States, Spain, United Kingdom
Celyad Oncology SA
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

Unresectable Metastatic Colorectal Cancer

Belgium, United States
PharmAbcine
Merck Sharp & Dohme LLC

Recruiting

Olinvacimab With Pembrolizumab in Patients With mTNBC

Metastatic Triple-Negative Breast Cancer

Australia

Search clinical trials for: Keynote

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations